Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Poor antibody validation wastes millions of biological samples, but solutions exist (opens in a new tab)

medicalxpress.com · 2026-10-06

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One key claim is not backed by the study. One other point was not covered by the paper.

  • 1 supported
  • 1 overstated
  • 1 not supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

Two claims go beyond the study. One overstates it and one isn't supported at all. One claim the study doesn't address.

  • 1 supported
  • 1 overstated
  • 1 not supported
  • 1 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not supportedIn the second study, 32 international experts reached consensus on 15 actions judged both effective and feasible for implementation by 2030, while another 15 actions were considered effective but of uncertain feasibility.View evidenceHide evidence

As stated32 experts; 15 actions; 15 additional actions

Why this verdict

The supplied paper profile contains no Delphi consensus study, no 32-expert panel, and no finding that 15 actions were both effective and feasible by 2030 with another 15 effective but of uncertain feasibility. This may relate to a separate paper mentioned by the story, but it is not supported by the supplied PaperScientificProfile.

Claim 2 of 4OverstatedA widespread failure to validate research antibodies before use is estimated to lead to the avoidable waste of millions of animal and human tissue samples worldwide.View evidenceHide evidence

As statedmillions of animal and human tissue samples

Why this verdict

The abstract-level profile supports that publications using poorly performing antibodies often lacked reported validation evidence and that conservative extrapolation yields global estimates in the millions. However, the headline frames this as antibodies not being validated before use causing avoidable waste of millions of samples. The paper profile more carefully distinguishes reported absence of validation evidence from actual non-validation, describes many samples as "at risk of waste," and notes a narrower definition of "waste" tied to withdrawn reagents. The headline therefore outruns the nuance even though the article mentions extrapolation in its caveats.

1

Study evidence

Among 760 publications where antibody validation status could be confirmed, only 120 (15.8%) presented any validation evidence.120/760 (15.8%)

“...systematic analysis of 785 publications”
2

Study evidence

Among 760 publications where validation status could be confirmed, 640 (84.2%) presented no validation evidence; these 640 papers reported a minimum of 8,064 animal samples and 4,424 human tissue samples used with antibodies shown to perform poorly, which the authors describe as "samples at risk of waste."

“The remaining 640 papers reported a minimum of 8,064 animal samples and 4,424 human tissue samples used with antibodies of demonstrated poor performance and without evidence of fitness for the specific experimental purpose; we describe these as samples at risk of waste.”
Claim 3 of 4Not coveredThe papers lacking antibody validation were reported to have used at least 8,064 animal samples and 4,424 human tissue samples, and the researchers extrapolated that millions of samples have been consumed globally without adequate validation.View evidenceHide evidence

As statedat least 8,064 animal samples and 4,424 human tissue samples; lower-bound global estimate of 4 million to 7 million animal samples and 6 million to 11 million human tissue samples

Why this verdict

The abstract-level profile supports the minimum counts of 8,064 animal samples and 4,424 human tissue samples in 640 publications lacking validation evidence, and it supports a conservative extrapolation to lower-bound, order-of-magnitude global estimates in the millions. But the presentation’s stated specific global ranges of 4–7 million animal samples and 6–11 million human tissue samples, along with the detailed extrapolation basis, are not available in the supplied abstract-level profile. The broader claim is directionally consistent, but the exact magnitude is not verifiable at this depth.

1

Study evidence

Among 760 publications where antibody validation status could be confirmed, only 120 (15.8%) presented any validation evidence.120/760 (15.8%)

“...systematic analysis of 785 publications”
2

Study evidence

Among 760 publications where validation status could be confirmed, 640 (84.2%) presented no validation evidence; these 640 papers reported a minimum of 8,064 animal samples and 4,424 human tissue samples used with antibodies shown to perform poorly, which the authors describe as "samples at risk of waste."

“The remaining 640 papers reported a minimum of 8,064 animal samples and 4,424 human tissue samples used with antibodies of demonstrated poor performance and without evidence of fitness for the specific experimental purpose; we describe these as samples at risk of waste.”
Claim 4 of 4SupportedThe first study analyzed focus groups, a survey, and 785 publications linked to antibodies that had failed rigorous knockout-controlled testing, and found that among 760 publications with determinable status, only 120 (15.8%) presented any validation evidence.View evidenceHide evidence

As stated785 publications; 760 assessable publications; 120 (15.8%) with validation evidence

Why this verdict

The profile reports focus groups, a survey, and a systematic analysis of 785 publications linked to poorly performing antibodies characterized with knockout controls. It also reports that validation status could be confirmed for 760 publications and that 120/760, or 15.8%, presented any validation evidence. This matches the story claim at abstract depth.

1

Study evidence

Social factors substantially influence antibody selection, with previous laboratory use and peer recommendations identified as important influences.

“Using focus groups (n=12)... we examined how researchers select and validate antibodies”
2

Study evidence

A large majority of surveyed researchers (72.0%) reported having used at least one recommended antibody validation method.72.0%

“Using... surveys (n=107)... we examined how researchers select and validate antibodies”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The survey found that 72.0% of surveyed researchers reported using at least one recommended antibody validation method.

    This finding complicates a simple narrative of universal failure to validate and is not mentioned in the story presentation or caveats.

    From Cross-sectional questionnaire survey

  • The paper distinguishes 'samples at risk of waste' from a narrower use of 'waste' for samples used with reagents since withdrawn from sale.

    The story caveats mention extrapolation but do not preserve this distinction; this matters because several story claims use stronger waste language.

    From secondary_data

  • A key limitation is that the publication analysis detects reported validation evidence; validation may have been performed but not reported.

    The story says papers lacked validation or that antibodies were not validated, but the abstract-level profile supports absence of reported validation evidence. The caveats do not mention possible unreported validation.

    From Systematic analysis of publications linked to poorly performing antibodies

  • The paper identifies researcher-reported barriers to validation, including time, cost, and lack of supervisor support, and support for open data sharing, dedicated validation funding, and publisher requirements.

    These barriers and proposed solutions are material to the paper’s interpretation but are not included in the story presentation’s claims, which instead emphasizes a separate Delphi consensus not present in the supplied profile.

    From Focus groups; Cross-sectional questionnaire survey

5 things the story did carry across
  • The paper includes mixed-methods researcher evidence: 12 focus groups and a survey of 107 researchers about antibody selection, validation practices, barriers, and solutions.
  • The central publication analysis searched 785 publications; validation status was confirmable for 760; only 120/760 (15.8%) presented any validation evidence.
  • The analysis was based on antibodies shown to perform poorly in a curated knockout-control characterization dataset; 97/614 antibodies failed across all tested applications.
  • The 640 publications lacking reported validation evidence contained minimum counts of 8,064 animal samples and 4,424 human tissue samples used with poorly performing antibodies.
  • The global sample estimates are conservative, lower-bound, order-of-magnitude extrapolations, and the abstract-level profile does not provide the detailed assumptions or uncertainty bounds.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataSystematically assess how often antibody validation evidence is reported in publications linked to poorly performing antibodies, and estimate downstream animal/human tissue samples placed at risk of waste.Systematic analysis of publications linked to poorly performing antibodiesExpand

In plain English

Systematic analysis of publications linked to antibodies shown by rigorous characterisation to perform poorly, extracting whether the publications presented any validation evidence; among 760 publications with confirmable validation status, 120 (15.8%) presented any validation evidence, and the remaining 640 papers reported at minimum 8,064 animal samples and 4,424 human tissue samples used with antibodies of demonstrated poor performance and without evidence of fitness for purpose.

Key findings

  • Among 760 publications where antibody validation status could be confirmed, only 120 (15.8%) presented any validation evidence.120/760 (15.8%)
  • In the 640 publications that did not present validation evidence and were linked to poorly performing antibodies, the authors identified at minimum 8,064 animal samples and 4,424 human tissue samples used with those antibodies and without evidence of fitness for the specific experimental purpose.
“...systematic analysis of 785 publications”
What this piece can’t prove
  • Assessment relies on what is reported in publications; validation work that was performed but not reported would not be captured.
  • Counts of animal and human samples are minima extracted from the publications and may under-represent the full extent of samples used.
  • Linkage between publications and specific antibodies depends on reporting in the publications and on the matching strategy used; mislinkage or missed links could affect counts.

1 further detail could not be confirmed from the summary.

2otherQuantify how researchers select and validate antibodies, including the role of social factors and barriers/solutions to validation.Focus groupsExpand

In plain English

Focus-group qualitative study (n=12) exploring how researchers select and validate antibodies, identifying social influences on selection, perceived barriers to performing validation, and participant support for interventions to improve validation practices.

Key findings

  • Social factors substantially influence antibody selection, with previous laboratory use and peer recommendations identified as important influences.
  • Researchers report primary barriers to performing systematic antibody validation are time, cost, and lack of supervisor support.
“Using focus groups (n=12)... we examined how researchers select and validate antibodies”
What this piece can’t prove
  • Small qualitative sample as reported in abstract (n=12); limits generalisability.
  • Abstract does not report participant selection, characteristics, or exact analytic methods, limiting appraisal of potential selection bias and analytic rigor.
  • Findings are based on self-reported perceptions and may not reflect actual practices or prevalence across the wider research community.
3human in vivoQuantify how researchers select and validate antibodies, including the role of social factors and barriers/solutions to validation.Cross-sectional questionnaire surveyExpand

In plain English

Cross-sectional questionnaire survey of researchers (n=107) assessing how antibodies are selected and validated, including self-reported use of recommended validation methods, perceived influences on selection, and barriers and solutions to validation.

Key findings

  • A large majority of surveyed researchers (72.0%) reported having used at least one recommended antibody validation method.72.0%
  • Researchers reported that antibody selection is substantially influenced by social factors such as previous laboratory use and peer recommendations.
“Using... surveys (n=107)... we examined how researchers select and validate antibodies”
What this piece can’t prove
  • Survey data are self-reported and subject to recall and social desirability bias.
  • Cross-sectional design precludes causal inference about determinants of validation practices.

2 further details could not be confirmed from the summary.

4secondary dataSystematically assess how often antibody validation evidence is reported in publications linked to poorly performing antibodies, and estimate downstream animal/human tissue samples placed at risk of waste.secondary dataExpand

In plain English

The authors systematically quantified how many animal and human tissue samples were used in publications that reported use of antibodies later shown to perform poorly and that provided no validation evidence for the specific application. From 760 publications where validation status could be confirmed, 640 lacked any validation evidence; these 640 papers together reported a minimum of 8,064 animal samples and 4,424 human tissue samples described as "samples at risk of waste." The paper further distinguishes a narrower definition of "waste" (samples used with reagents since withdrawn from sale) and reports a conservative extrapolation that yields lower-bound, order-of-magnitude global estimates in the millions of animal and human tissue samples.

Key findings

  • Among 760 publications where validation status could be confirmed, 640 (84.2%) presented no validation evidence; these 640 papers reported a minimum of 8,064 animal samples and 4,424 human tissue samples used with antibodies shown to perform poorly, which the authors describe as "samples at risk of waste."
  • Using a narrower definition of 'waste' (samples used with reagents since withdrawn from sale), conservative extrapolation from the observed data yields lower-bound, order-of-magnitude estimates of millions of animal and human tissue samples consumed globally because of inadequate antibody validation.
“The remaining 640 papers reported a minimum of 8,064 animal samples and 4,424 human tissue samples used with antibodies of demonstrated poor performance and without evidence of fitness for the specific experimental purpose; we describe these as samples at risk of waste.”
What this piece can’t prove
  • Reported sample counts are minimums based on what was available in the analysed publications and may under-represent actual sample use.

2 further details could not be confirmed from the summary.

5secondary dataDemonstrate, from a curated dataset of antibodies characterized with knockout controls, the rate at which antibodies fail across tested applications.secondary dataExpand

In plain English

Analysis of a curated dataset of 614 antibodies characterized using knockout (KO) controls found 97 antibodies (15.8%) that failed across all tested applications.

Key findings

  • In a curated dataset of 614 antibodies characterised using knockout controls, 97 antibodies (15.8%) failed across all tested applications.15.8% (97/614)
“From a dataset of 614 antibodies subjected to rigorous characterisation using knockout controls, 97 (15.8%) failed across all tested applications”
What this piece can’t prove
  • Unclear whether the 614-antibody dataset is representative of broader reagent stocks or biased toward particular antibody types, vendors, targets, or applications.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Europe PMC, Crossref, PubMed · 16 candidate papers

Candidate

Ranking, Not Estimating: Out-Of-Sample Validation of Machine Learning on the UN Food Loss and Waste Database

2026 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.